Abstract
Over the last decade or so, a number of key international organizations have filtered the large body of emerging evidence examining the treatment of men with LUTS. This chapter distils these treatment guidelines starting with the most recent first. Most management algorithms divide treatment into conservative, medical, and surgical. There is also focus on acute and chronic urinary retention and nocturia. Fortunately, there is reasonable overlap signalling sound evidence and advice.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Curr Opin Urol. 2012;22(1):34–9. Epub 2011/11/30.
Emberton M. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract. 2010;64(10):1425–35. Epub 2010/06/29.
Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology. 2011;78(1):3–9. Epub 2011/05/24.
Norg RJ, van de Beek K, Portegijs PJ, van Schayck CP, Knottnerus JA. The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial. Br J Gen Pract. 2006;56(533):938–44. Epub 2006/11/30.
Strope SA, Wei JT, Smith A, Wilt TJ, Saigal CS, Elliott SP. Evaluative care guideline compliance is associated with provision of benign prostatic hyperplasia surgery. Urology. 2012;80(1):84–9. Epub 2012/05/23.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–40. Epub 2013/03/13.
Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007;334(7583):25. Epub 2006/11/23.
National Institute for Health and Care Excellence. The management of lower urinary tract symptoms in men. CG 97. 2010. London: National Institute for Health and Care Excellence.
Nickel JC, Mendez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 update: guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010;4(5):310–6. Epub 2010/10/15.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803. Epub 2011/03/21.
Mcconnell Pa J, Denis L, Khoury Cr S. Male lower urinary tract dysfunction. Paris: Health Publications; 2006.
Hong SJ, Ko WJ, Kim SI, Chung BH. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol. 2003;44(1):94–9; discussion 99–100. Epub 2003/06/20.
Bereczky Z, Bolus M, Chetty P, du Toit W, Enslin J, Haffejee M, et al. Management of benign prostatic hyperplasia – South African Urological Association Guideline. S Afr Med J. 2006;96(12 Pt 3):1275–9. Epub 2007/01/26.
Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93(7):985–90. Epub 2004/05/15.
McNeill SA, Hargreave TB, Roehrborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology. 2005;65(1):83–9; discussion 89–90. Epub 2005/01/26.
Abrams PH, Dunn M, George N. Urodynamic findings in chronic retention of urine and their relevance to results of surgery. Br Med J. 1978;2(6147):1258–60. Epub 1978/11/04.
Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated detrusor underactivity. BJU Int. 2005;96(9):1295–300. Epub 2005/11/17.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Thiruchelvam, N. (2014). Treatment Algorithms: When to Treat and Whom?. In: Chapple, C., Tubaro, A. (eds) Male LUTS/BPH Made Easy. Springer, London. https://doi.org/10.1007/978-1-4471-4688-9_4
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4688-9_4
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4687-2
Online ISBN: 978-1-4471-4688-9
eBook Packages: MedicineMedicine (R0)